Brightplex® TCE and brightplex® MDSC assays combination improves advanced NSCLC patients’ stratification under anti-PD1/L1 immunotherapy in the PIONeeR project
| Type | : | ACL |
|---|---|---|
| Nature | : | Production scientifique |
| Au bénéfice du Laboratoire | : | Non |
| Statut de publication | : | Publié |
| Année de publication | : | 2022 |
| Auteurs (36) | : | GHEZALI L LANDRI Marcellin MONVILLE F LECA V VASSE T HAMDAD C MERCADAL M VANHILLE L KASSAMBARA A SBARRATO T LE RAY M ROUMIEUX M MALKOUN R RESSEGUIER N BOYER A AUDIGIER-VALETTE C MARTINEZ S PEGLIASCO H RAY P FALCHERO L SERRE A CLOAREC N LEBAS L HOMINAL S BARRÉ P ZAHI S FRIKHA A BORY P LABORDE L MAZIÈRES J MARTIN V MAZIÈRES J PÉROL M GREILLIER L BARLESI F FIESCHI J |
| Revue scientifique | : | The Journal for ImmunoTherapy of Cancer |
| Volume | : | 10 |
| Fascicule | : | |
| Pages | : | |
| DOI | : | 10.1136/jitc-2022-SITC2022.0701 |
| URL | : | - |
| Abstract | : | Background Immune Checkpoint Inhibitors (ICIs) are associated with long-term survival in ~20% of advanced NSCLC patients while biological mechanisms triggering resistance are not fully elucidated. Myeloid-Derived Suppressor Cells (MDSC) might however play a key role. The PIONeeR project (NCT03493581, ANR-17-RHUS-0007) aims to predict the response/resistance to PD1/L1 ICIs in advanced NSCLC patients through comprehensive agnostic multiparametric biomarker assessment. Here, the combination of both lymphoid and myeloid lineages infiltration in the tumor is evaluated on tissue collected at diagnosis to predict outcome. |
| Mots-clés | : | - |
| Commentaire | : | - |
| Tags | : | - |
| Fichier attaché | : | - |
| Citation | : |
Ghezali L, Landri M, Monville F, Leca V, Vasse T, Hamdad C, Mercadal M, Vanhille L, Kassambara A, Sbarrato T, Le Ray M, Roumieux M, Malkoun R, Resseguier N, Boyer A, Audigier-Valette C, Martinez S, Pegliasco H, Ray P, Falchero L, Serre A, Cloarec N, Lebas L, Hominal S, Barré P, Zahi S, Frikha A, Bory P, Laborde L, Mazières J, Martin V, Mazières J, Pérol M, Greillier L, Barlesi F, Fieschi J (2022) Brightplex® TCE and brightplex® MDSC assays combination improves advanced NSCLC patients’ stratification under anti-PD1/L1 immunotherapy in the PIONeeR project. J immunotherap cancer 10 | doi: 10.1136/jitc-2022-SITC2022.0701
|